Artemisinin acts by inhibiting *Plasmodium falciparum* Ddi1, a retropepsin, resulting into the accumulation of ubiquitinated proteins

Noah Machuki Onchieku^{1,2}, Sonam Kumari³, Rajan Pandey⁴, Vaibhav Sharma¹, Mohit Kumar³, Arunaditya Deshmukh¹, Inderjeet Kaur¹, Asif Mohammed³, Dinesh Gupta⁴, Daniel Kiboi², Naseem Gaur³, Pawan Malhotra^{*}

¹Malaria Biology Group, International Centre for Genetic Engineering, and Biotechnology, Aruna Asaf Ali Marg, New Delhi, India

²Department of Biochemistry, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya

³Yeast Biofuel Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi, India

⁴Translational Bioinformatics Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi, India

⁵Parasite Cell Biology Group, International Centre for Genetic Engineering, and Biotechnology, Aruna Asaf Ali Marg, New Delhi, India

*Corresponding author: Pawan Malhotra

E-Mail: pawanmal@gmail.com

Running title: Artemisinin inhibits the activity of *Plasmodium* Ddi1

Keywords: Artemisinin, *Plasmodium falciparum*, DNA Damage, Ddi1, Ubiquitin-Proteasome Pathway

Abstract

Reduced sensitivity of the human malaria parasite, *Plasmodium falciparum*, to Artemisinin and its derivatives (ARTs) threatens the global efforts towards eliminating malaria. ARTs have been shown to cause ubiquitous cellular and genetic insults, which results in the activation of the unfolded protein response (UPR) pathways. The UPR restores protein homeostasis, which otherwise would be toxic to cellular survival. Here, we interrogated the role of DNA-damage inducible protein 1 (*PfDdi1*), a unique proteasome-interacting retropepsin in mediating the actions of the ARTs. We demonstrate that *PfDdi1* is an active A₂ family protease that hydrolyzes ubiquitinated substrates. We further show that treatment with ARTs lead to the accumulation of ubiquitinated proteins in the parasites and blocks the destruction of the ubiquitinated substrates by *PfDdi1*. Besides, whereas the *PfDdi1* is predominantly localised in the cytoplasm, exposure of the parasites to ARTs leads to DNA fragmentation and increased recruitment of the *PfDdi1* into the nucleus. Furthermore, *Ddi1* knock-out *Saccharomyces cerevisiae* cells are more susceptible to ARTs and the *PfDdi1* protein robustly restores the corresponding functions in the knock-out cells. Together, these results show that ARTs act by inducing DNA and protein damage, and impairing the damage recovery by inhibiting the activity of *PfDdi1*, an essential ubiquitin-proteasome retropepsin.

Introduction

Artemisinin and its derivatives (ARTs) are components of mainstay drugs for the treatment of malaria caused by the *Plasmodium falciparum* parasite¹. However, the emergence and spread of resistance towards the artemisinins poses an imminent danger towards the global efforts to eliminate malaria². Historically, the spread of malaria drug resistance mechanisms from South East (SE) Asia to India is a crucial “stepping stone” to the eventual introduction in Africa^{3,4}. Regrettably, recent evidence has shown the presence of Artemisinin resistant *P. falciparum* in India⁵. This situation does not only pose a grave danger to public health in these countries but also in sub-Saharan Africa, a continent most affected by malaria¹. Whereas there is the most reliable evidence linking mutations in the Kelch domain protein (K13-propeller; PF3D7_1343700) with parasite tolerance to artemisinin⁶, insufficient knowledge on the molecular mechanisms of artemisinin action hampers definitive conclusion. Understanding the mechanisms of action and resistance of artemisinin, therefore, would not only provide a basis for identifying new targets but also be useful to the development of new alternative compounds that thwart and antagonize the emergence of resistance.

Recent reports have demonstrated the promiscuous nature of artemisinin-mediated cellular damages^{7–11}. For instance, besides the ubiquitous protein insults¹², Artemisinin has been attributed to DNA damage mediated by reactive oxygen species (ROS)⁹. Consequently, the damage would be expected to trigger stress response or unfolded protein response (UPR) pathways^{13,14}, such as the ubiquitin-proteasome system (UPS)¹². The UPS degrades unfolded/damaged proteins that would otherwise be toxic to cells. Interestingly, evidence has associated the K13-propeller protein with ubiquitination^{8,15}, and inhibitors of the UPS have been shown to enhance the action of artemisinin against *P. falciparum* parasites^{16–18}. Artemisinin

inhibits the UPS and the changes to this system mediate parasite tolerance to artemisinin pressure^{12,16,19}. However, molecular data on the role of the UPS in mediating the action/resistance of artemisinin in *P. falciparum* parasites remains scanty.

PfDdi1, an essential retropepsin in the UPS^{20,21}, has been shown to compensate for proteasome dysfunction and its knock out leads to polyubiquitination of proteins in both yeast and *Toxoplasma gondii* cells^{22–24}. It is feasible, therefore, to speculate that artemisinin might be compromising the activity of *PfDdi1* in restoring protein homeostasis following the damage. Here, we identify the *PfDdi1*, commonly referred to as the proteasome shuttle protein, and investigate its role in mediating the actions of artemisinin. Binding and enzymatic assays demonstrate that *PfDdi1* is an active proteasome retropepsin that cleaves ubiquitinated substrates. We show that artemisinin enhances polyubiquitination of parasite proteins and inhibits the activity of *PfDdi1* in digesting the ubiquitinated proteins. In addition, the parasites' exposure to artemisinin induces DNA fragmentation and increases recruitment of the *PfDdi1* protein into the nucleus. Besides, using yeast complementation studies, we show that whereas *PfDdi1* is dispensable in yeast, *PfDdi1* deficient *S. cerevisiae* cells display more susceptibility to artemisinin pressure. The expression of *PfDdi1* restores the functions in the corresponding Ddi1-knock out yeast cells. Our work thus gives insights into the role of the *PfDdi1* and validates it as a vulnerable protein that could be the basis for the development of new chemotherapies against the *P. falciparum* malaria.

Results

PfDdi1 is an active A₂ family protease that hydrolyzes polyubiquitin substrates

Whereas *P. falciparum* parasites express three proteasome interacting proteins (PIPs); *PfDdi1*, Rad23 and Dsk2, deletion of only *PfDdi1* has been proven to be toxic to the cells, thus indispensable^{20,21,25}. Compared to the other *PfPIPs*, *PfDdi1* harbors a unique retroviral-protease like (RVP) domain besides the conventional ubiquitin-like (UBL) domain. Despite being characterized in other organisms, Ddi1 remains poorly understood in *Plasmodium* spp. To functionally characterize the role of the *PfDdi1* if any, we cloned, and expressed a histidine-tagged full length *PfDdi1* gene (PF3D7_1409300) in Rosetta (DE3) cells. The expressed recombinant *PfDdi1* protein was analyzed by both Coomassie staining and Western blotting with α -His antibodies. The *PfDdi1* protein was then purified under non-denaturing conditions, and it showed two discrete bands of ~44kDa and ~34 kDa sizes on SDS PAGE, suggesting that the ~34 kDa band is probably a processed fragment of the *PfDdi1* protein (Fig. 1a and Supplementary Fig. 1). To confirm whether the ~34kDa band is indeed a processed product of the intact *PfDdi1* protein, we analysed both bands by LC-MS/MS. The proteome analysis showed that the peptides identified in the LC-MS/MS analysis for each of the fragments corresponded to the *PfDdi1* protein and interestingly, they both had the aspartic catalytic signature motif (DSG) (Supplementary Fig. 2). The purified recombinant *PfDdi1* protein was then used to raise antibodies in mice and rabbits. The specificity of the antibodies to detect native *PfDdi1* was assessed by Western blot using trophozoite-rich *P. falciparum* blood stage parasite lysate. The mice or rabbit anti-*PfDdi1* antibodies stained a band of the size expected for *PfDdi1* in *P.*

falciparum (Fig. 1b). Since *PfDdi1* possesses a retroviral-like protease (RVP) domain, we next assessed the pepsin/cathepsin D, retropepsin or proteasome activity of the purified recombinant *PfDdi1* protein using the Bz-RGFFP-MNA, DABCYL-Gaba-SQNYPIVQ-EDANS or Suc-LLVY-AMC substrates, respectively. Unlike the cathepsin D substrate, 2.0 μ M of the enzyme hydrolyzed DABCYL-Gaba-SQNYPIVQ-EDANS or Suc-LLVY-AMC at pH 5.0. The enzyme was more active on the retropepsin substrate, with a catalytic efficiency of $\sim 3.8 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$ ($K_m = 4.135 \pm 0.280 \mu\text{M}$), compared to the proteasome specific substrate, with an efficiency of $\sim 8.0 \times 10^4 \text{ M}^{-1} \text{ s}^{-1}$ ($K_m = 21.85 \pm 4.135 \mu\text{M}$) (Fig. 1c). Due to its ability to hydrolyze proteasome substrates, coupled with previous evidence that *Ddi1* compensates for proteasome dysfunction²², we hypothesized that the *PfDdi1* might harbor the ability to degrade polyubiquitinated proteins/substrates. Polyubiquitination serves as a recognition signal for the proteasome. Our data showed that, incubation of K⁴⁸-linked polyubiquitin substrate with 2.0 μ M *PfDdi1* enzyme led to significant cleavage of the substrate (Fig. 1d). Together, these findings demonstrate that *PfDdi1* is an active retroviral protease that hydrolyzes polyubiquitin/proteasome substrates.

***PfDdi1* enzyme degrades Bovine serum albumin, BSA**

Having demonstrated the ability of the recombinant *PfDdi1* protein to hydrolyze peptide substrates, we assessed the capacity of the enzyme to degrade macromolecules. Compared with the control (BSA alone), incubation of BSA with the *PfDdi1* protein resulted in the degradation of BSA, at pH 5.0. SDS-PAGE analysis of the test assay showed a significantly reduced BSA band intensity ($\sim 66\text{kDa}$) (Fig. 1e and f). On the other hand, the *PfDdi1* could not hydrolyze BSA at pH 7.0 (Supplementary Fig. 3). In *Leishmania major*, an acidic pH has been shown to be more favourable to the *Ddi1* activity.²⁶

Artemisinin increases polyubiquitination in *P. falciparum* and blocks the activity of *PfDdi1* in degrading the polyubiquitinated substrates

Artemisinin has been shown to cause widespread damages to parasite proteins^{7,8,11}. The damage invokes the unfolded protein response pathways as a means of tidying up. Here, we assessed the impact of artemisinin on global protein ubiquitination as well as on the activities of the *PfDdi1* enzyme. Exposure of trophozoite-rich 3D7 *P. falciparum* parasites to 1.0 μ M of artemisinin (a physiologically relevant dose²⁷) for 2 hours resulted into accumulation of polyubiquitinated proteins. Similarly, Dihydroartemisinin (DHA; 1.0 μ M, a biologically active ART metabolite) and MMS (0.05%) led to enhanced polyubiquitination, but not Lopinavir (50 μ M) (Fig. 2a). The rapid protein polyubiquitination under artemisinin pressure invoked thoughts about its potential inhibition ability against the *PfDdi1* enzyme activities. Indeed, artemisinin and its derivative, DHA, significantly inhibited the ability of *PfDdi1* to degrade the polyubiquitinated substrate. Besides, artemisinin significantly inhibited the activity of *PfDdi1* with both the retropepsin (71.4%) and proteasome (65.9%) specific substrates, as well as with BSA (Fig. 2b-f). Lopinavir (50 μ M), a known HIV protease inhibitor, produced about 23% inhibition. Surprisingly, whereas MMS (0.05%) led to increased polyubiquitination, it enhanced the activities of *PfDdi1* proteins against all the substrates (Fig. 2b-f). These data demonstrates the dual mechanisms of action of the artemisinins; by causing protein damage in the parasite and blocking tidying up by inhibiting the activities of *PfDdi1* enzyme.

Artemisinin treatment leads to increased recruitment of *Pf*Ddi1 into the nucleus following DNA damage

Artemisinin has been shown to induce DNA damage in malaria parasites as demonstrated by comet assays⁹. However, data on the nature of the DNA damage remains elusive. Using the *in situ* DNA fragmentation (TUNEL) assay, we observed DNA fragmentation (direct TdT-mediated dUTP nick end labeling) in more than 90% of the *P. falciparum* parasites following a two-hour exposure to artemisinin (Fig 3a). To gain insights into the possible molecular events accompanying the artemisinin-specific DNA fragmentation, we employed immunofluorescence assays (IFA), using anti-*Pf*Ddi1 antibodies, to evaluate the expression profile of the *Pf*Ddi1 protein, under drug pressure. Previously, Ddi1 was shown to repair DNA-protein crosslinks (DPCs) in yeast cells²⁸. Our data showed that, whereas *Pf*Ddi1 is predominantly expressed in the cytoplasm, artemisinin and DHA treatment led to increased recruitment of the protein into the *P. falciparum* nucleus (Fig. 3b and c). Thus, whereas we have not shown the exact DNA repair mechanism, the shift in expression is likely to be a causal relation between the DNA fragmentation and *Pf*Ddi1 repair strategies.

Artemisinin binds and stably interacts with the highly conserved aspartic protease motif “DSG” in *Pf*Ddi1 protein

Having established the effect of artemisinin on the *Pf*Ddi1 protease activity, we carried out surface plasmon resonance (SPR) and Bio-Layer Interferometry (BLI) based binding assays, as well as computational analysis to delineate the exact interaction between *Pf*Ddi1 and artemisinin. Briefly, over 8500 response units (RU) or up to a maximum of 0.8nm shift of the recombinant

PfDdi1 was immobilized via the amine coupling chemistry (CM5 chip) or streptavidin-biotin capture (Octet biosensors), respectively. Depending on the buffer in which the compounds were dissolved, we used either HBS-EP or DMSO as running buffer. Both artemisinin and MMS showed high affinity interactions with *PfDdi1* in both binding assays with K_D values of 1.06×10^{-6} / 1.56×10^{-6} , and 1.70×10^{-6} / 2.51×10^{-5} respectively, while lopinavir showed lower binding affinities with a K_D value 2.22×10^{-4} / 5.62×10^{-4} , in SPR and BLI assays (Fig. 4a-c). This binding was specific as none of the compounds showed interaction with the heme detoxification protein (HDP) (Supplementary fig. 5). On the other hand, PFAM and INTERPROSCAN search revealed the presence of two conserved domains in the *PfDdi1* sequence: N-terminal Ubiquitin-like domain (4-74aa) and a retroviral-like protease domain (RVP; 222-345aa) (Supplementary Fig. 1a and 5). Further, to know conservation among different species, we performed multiple sequence alignment of Ddi1 sequences from *P. falciparum*, *L. major*, yeast and human. The alignment analysis showed that *PfDdi1* had 95% query coverage and ~29% identity with human Ddi1 (hDdi1). In addition, all the aligned Ddi1 protein sequences showed higher conservation in the central RVP domain region as compared to the N- or C- terminal regions, with the presence of superimposed highly conserved aspartyl protease signature motif “D(S/T)G” (Supplementary Fig. 6).

As no crystal structure for *PfDdi1* protein is available so far, we generated a homology-based 3D model for *PfDdi1*. All attempts to generate complete stable 3D structure for *PfDdi1* (382aa) were futile. We then generated a partial 3D model for the *PfDdi1* RVP domain (243-366aa) using 4RGH, a human Ddi1 Homolog 2 protein, having 37% query coverage and 48.61% identity with the *PfDdi1*, as a template (Fig. 4b). The Ramachandran plot for the predicted model showed no residues in the disallowed region, confirming the good quality of the model. To assess

whether an artemisinin molecule binds to the protease domain region, we performed *in silico* docking using AutoDocktools. Here, site specific docking was performed using the predicted *PfDdi1* as a receptor and an artemisinin molecule as a ligand. Grid box was generated using nitrogen of Asp262 as the center (grid points xyz coordinates as 40, 40, 40 and spacing of 0.4Å), and the other default parameters were used for the screening. The docking analysis revealed *PfDdi1* protein binding with artemisinin in the active catalytic protease signature motif (DSG) (Fig. 4d). The free binding energy for the reaction was -5.81 kcal/mol. Hydrogen bonds were formed between artemisinin and Ser263 (in the catalytic DSG motif), with all the three active-site residues of the aspartyl proteases present within 4Å of artemisinin. Taken together, the binding and docking results suggest stable interaction between the *PfDdi1* protein and artemisinin, and possible inhibition of the *PfDdi1* protease activity by artemisinin.

***PfDdi1* restores the protein secretion phenotype in yeast cells**

To know whether the *PfDdi1* is a true orthologue of yeast *Ddi1*, we performed complementation studies in *S. cerevisiae* yeast cells. We singly disrupted the *ScDdi1* gene, by homologous recombination, and assayed whether the *PfDdi1* ortholog could complement the phenotypes in the knockout yeast cells. Cells bearing a *Ddi1* gene disruption were seen to grow normally. However, as has been shown previously²⁹, our data showed that *Ddi1Δ* yeast cells secreted significantly higher protein levels into the media (Fig. 5a). On average, *Ddi1Δ* yeast cells secreted more than ~30% of proteins into the media, compared with the wild type strain. To test whether *PfDdi1* restores the wild-type proteins secretion phenotype, we cloned a gene encoding the full-length *PfDdi1* into a yeast expression vector pGPD2. The ligated construct was transformed into the *Ddi1Δ* yeast cells. The *PfDdi1* construct was able to revert the protein

secretion phenotype to WT level, i.e the level of protein secretion decreased in comparison to the knock-out strain (Fig. 5a).

Ddi1 deficient yeast cells are more susceptible to Artemisinin pressure

It had been previously shown that mutations in some DNA repair genes confer resistance to Artemisinin³⁰. Moreover, DNA damaging agents have been shown to perturb and induce transcriptional changes in 21% of the *P. falciparum* genome¹⁰. These changes involve up-regulation of the genes of the DNA repair machinery. Similarly, yeast studies demonstrated that DNA damaging agents trigger differential expression in one third of the entire *S. cerevisiae*'s gene pool³¹. We reasoned that since the proteasome is central to the repair or disposal of damaged cellular components, the yeast cells lacking the Ddi1 might be more susceptible to DNA damaging agents. We, therefore, incubated equal amounts of yeast cells with different drugs and DNA Damaging agents such as artemisinin, chloroquine, lopinavir, hydroxyurea, MMS, and camptothecin and measured sensitivity using both OD (growth curves) and spotting tests. Our results demonstrated that Ddi1Δ yeast cells were more susceptible to artemisinin (12μM). These Ddi1Δ cells were also hypersensitive to DNA damage drugs; hydroxyurea, MMS, and camptothecin (Fig.5b and c). Together, these results augments our observations in *P. falciparum* and demonstrate that *Pf*Ddi1 reduces the sensitivity of the cells to artemisinin insults, and artemisinin works similar to the known DNA dmaging agents.

Discussion

The spectrum of drugs to which the human malaria parasite, *Plasmodium falciparum* has not evolved tolerance is rapidly diminishing. Reports on decreased sensitivity of the parasites towards the recommended first-line treatment for *P. falciparum* malaria, artemisinin, threatens the global efforts to combat the disease. To circumvent the resistance, improve the efficacy or generate new drugs, it's critical to understand the mechanisms of action/resistance of the artemisinin. Since it has been shown that artemisinin causes indiscriminate damage to parasite cellular proteins⁷⁻¹¹, recruitment of the parasite protein repair machinery might be pivotal in assuring parasite growth fitness. Besides, artemisinin compromises the functions of the parasite proteasome and synergizes with proteasome inhibitors in the killing of artemisinin resistant parasites^{12,18}. Here, we investigate the mode of action of artemisinin on the parasite proteasome machinery. Expression and activity analysis of *PfDdi1*, a proteasome shuttle protein with an unusual RVP domain, show that *PfDdi1* is an active A2 aspartyl protease that hydrolyzes proteasome substrates, including polyubiquitin proteins. However, the enzyme could not catalyze the hydrolysis of Bz-RGFFP-MNA, a cathepsin D substrate. This activity is in line with earlier reports that showed *L. major* Ddi1 as an active aspartyl proteinase²⁶, as well as *ScDdi1* as a ubiquitin-dependent protease that acts on polyubiquitinated substrates²³. The ability of *PfDdi1* to cleave polyubiquitinated substrates suggests that the *PfDdi1* enzyme might not only be a shuttle protein but could inherently degrade damaged proteins. Thus, the *PfDdi1* protein might be acting synergistically with the proteasome machinery to degrade the ubiquitinated proteins. Indeed, previous reports have demonstrated that Ddi1 compensates for proteasome dysfunction in *Caenorhabditis elegans*²². In addition, deletion of Ddi1 (Δ Ddi1) in *T. gondii* results into accumulation of ubiquitinated proteins, a phenomenon enhanced by double deletion (Δ Ddi1 and

Δ Rad23)²⁴. Therefore, the essentiality of the *PfDdi1* advocates its multiple roles in parasite life cycle and negates any redundancy in its functions. On the other hand, *in silico* data reveals that unlike most of the Ddi1 analogs, *PfDdi1* lacks the UBA domain, thus suggesting that the UBA domain does not contribute to the protease activity of the Ddi1 protein. These results are consistent with the observation made earlier for *ScDdi1*, which shows that the deletion of UBA domain had no effect on the activity of *ScDdi1*²³.

To further show that *PfDdi1* is a functional homolog of the *ScDdi1*, which is one of the best characterized Ddi1 protein, complementation studies were carried out in *S. cerevisiae* cells. Functional expression of the *PfDdi1* in *S. cerevisiae* cells showed its ability to restore disrupted phenotypes. We show that, unlike in *P. falciparum* where functional disruption of Ddi1 gene is deleterious, *ScDdi1* gene is not refractory to deletion in yeast cells. However, as previously reported²⁹, deletion of *ScDdi1* increased secretion of proteins to the growth media. Interestingly, despite the differences in the domain structure, the *PfDdi1* gene robustly complemented the yeast secretion phenotype. This observation might infer that the C-terminal UBA domain lacks crucial sequences associated with the suppression of protein secretion.

Since artemisinin has been shown to promiscuously target parasite proteins and induce DNA damage (Comet assay), we sought to define whether it also inhibits the activity of *PfDdi1*. We first demonstrate that, indeed, artemisinin causes protein damage which leads to piling up of polyubiquitinated proteins. This is in agreement with previous data which showed that the artemisinins induce polyubiquitination in the malaria parasite^{12,16}. On the other hand, we demonstrate that artemisinin causes DNA damage by directly inducing DNA fragmentation in the *P. falciparum* parasites. Interestingly, the exposure of the parasites to genotoxic artemisinin

insults causes increased recruitment of *PfDdi1* into the nucleus. This suggests that *PfDdi1* might be involved in the regulation of DNA damage response to artemisinin. Indeed, previous reports have implicated Ddi1 in the repair of DNA-protein crosslinks²⁸. The exact mechanism adopted by the *PfDdi1* in the DNA damage repair in the parasites remains of utmost interest. Enzyme inhibition assays showed that artemisinin blocked 71.4% or 65.9% of the activity of *PfDdi1* against the retropepsin or proteasome substrates, respectively. Besides, artemisinin significantly inhibited the degradation of polyubiquitinated substrates, a finding that unequivocally fortifies the inhibitory effect of artemisinin on the *PfDdi1* activities. However, lopinavir (50 μ M), a known HIV protease inhibitor, could only yield marginal inhibition (~23.5%) of the activity of *PfDdi1*, a retropepsin protease. In addition, interaction sensograms from binding assays and *in silico* modeling and docking studies showed high affinity binding between artemisinin and *PfDdi1*. To provide additional evidence on the role of Ddi1 in the mediation of artemisinin activities, we studied the growth fitness of Ddi1 deficient *S. cerevisiae* (*ScDdi1 Δ*) cells. This transgenic line showed differential susceptibilities to an array of DNA damage compounds as well as to artemisinin, the mainstay anti-malarial drug. *ScDdi1 Δ* cells were more susceptible to artemisinin pressure, compared to the wild type cells. Therefore, the observed increased susceptibility might be as a result of the *ScDdi1 Δ* cells' inefficiency to invoke DNA and protein repair upon artemisinin-induced damage. In fact, artemisinin has been shown to increase the generation of free radicals that chokes the yeast cell homeostasis³². Besides, artemisinin has been shown to elicit DNA damaging effect comparable to MMS, an alkylating agent¹⁰. Restoration of the WT growth fitness by the *PfDdi1* infers that the UBA domain plays an insignificant role in responding to artemisinin genotoxic insults.

These results thus enhance the evidence on the mode of action of artemisinin that has been earlier shown to kill the parasites via a two-step mechanism; causing ubiquitous protein damage and compromising parasite proteasome functions¹². Therefore, based on our data coupled with the previous observations, we propose that artemisinin exerts its pressure on the parasite by compromising the *PfDdi1* protein, an important player in the parasite protein homeostasis. The compromised *PfDdi1* does not only lose its ability to degrade the damaged proteins but also curtail its shuttling capacity, thus leading to accumulation of the damaged proteins and eventual death of the malaria parasite (Fig. 6).

In conclusion, here we show that *PfDdi1*, an essential *P. falciparum* protein, is an active A₂ family aspartic protease, with inherent abilities to degrade polyubiquitinated proteins. *PfDdi1* is a true orthologue of *ScDdi1* and could be involved in DNA damage repair strategies by the parasites. We further show that artemisinin, a first line drug against *P. falciparum* malaria, kills the parasites by inducing protein damage and inhibiting tidying up by blocking the activity of *PfDdi1*, a unique ubiquitin-proteasome retropepsin, that results in piling up of the damaged proteins. These results thus provide insight into the mode of action of artemisinin and pave the way for development of new antimalarial drugs targeting *PfDdi1*.

Methods

Ethics statement

All protocols were conducted in accordance with prior approvals obtained from the International Centre for Genetic Engineering and Biotechnology (ICGEB)'s Scientific Ethical Review Unit and the Institutional Animal Ethics Committee (IAEC; ICGEB/IAEC/02042019/MB-7).

Cloning, expression, and purification of recombinant *PfDdiI*

The *PfDdiI* gene (PF3D7_1409300) was amplified from genomic DNA using specific primers; *DdiI* forward 5'-GCGGATCCATGGATATGGTTTTTTATTACAATATCAGACG-3', reverse 5' GCGTCGACCTCGAGTAAATCATTGTTTGCATCAATG-3'. The PCR product was first cloned into pJET vector (Thermo Scientific) and then sub-cloned into pET-28b expression vector using *NcoI* and *XhoI* restriction sites (Thermo Scientific). The pET-28b clone was expressed in Rosetta (DE3) *Escherichia coli* cells (Invitrogen). The cells were grown to mid log phase, and then induced with isopropyl-1-thio- β -D galactopyranoside (IPTG, 1 mM) for 14 h at 16°C. The bacterial culture was harvested by centrifugation at 4000xg for 20 min. The cell pellet was re-suspended in lysis buffer (50 mM Tris·HCl at pH 8.0, 200 mM NaCl, 1.0% Triton X-100 and 1.0% PMSF) and then sonicated. The supernatant was collected by centrifugation at 9,000 rpm for 50 min, at 4°C. The soluble recombinant protein was purified using the Nickel-Nitrilotriacetic acid (Ni-NTA⁺; Qiagen) resin. Briefly, the protein was allowed to bind in 20 mM imidazole-containing binding buffer (50 mM Tris·HCl at pH 8.0 and 200 mM NaCl) for 3 h at 4 °C. The resin with bound protein was washed in 30 mM imidazole-containing binding buffer and then the bound protein was eluted in varying concentrations of the imidazole (50, 75, 100, 150, 200, 300 and 500 mM) in 50 mM Tris·HCl at pH 8.0 and 200 mM NaCl. The purified fractions were checked on SDS-PAGE and

Western blot analysis using α -His antibodies. All the pure fractions were pooled and dialyzed in the Tris-NaCl buffer (50 mM Tris-HCl pH 8, 200 mM NaCl), and then concentrated.

Generation of antibodies against *PfDdi1*

All animal protocols were conducted in accordance with prior approvals obtained from the International Centre for Genetic Engineering and Biotechnology (ICGEB)'s scientific review committee and the institutional animal ethics committee (ICGEB/IAEC/02042019/MB-7).

We used BALB/c inbred mice and female NZW rabbits to raise anti-bodies against the recombinant *PfDdi1*. The mice were immunized with 20 μ g of the protein while the rabbits were immunized with 200 μ g protein in the presence of complete/incomplete Freund's adjuvant, using the i.p. and s.c. modes of injection, respectively. After the third bleed, the antibody titers were quantified by ELISA. The specificity of the raised antibodies was analyzed on the recombinant *PfDdi1* protein and the *P. falciparum* parasite lysate.

PfDdi1 enzymatic assays

The aspartyl proteinase activity of the purified recombinant *PfDdi1* was probed against three substrates; Bz-RGFFP-4M β NA, DABCYL-Gaba-SQNYPIVQ-EDANS or Suc-LLVY-AMC (Bachem, Bubendorf, Switzerland), following the protocol described earlier²⁶. Briefly, 2.0 μ M of the recombinant *PfDdi1* was incubated with decreasing concentration (80 μ M-1.25 μ M) of each of the substrates in 100 mM sodium acetate buffer, at pH 5.0. Triplicate assays were carried out in a total volume of 200 μ l in 96 well opaque plates, for 4 h at 37 °C. Assays with Heme Detoxification Protein (*PfHDP*) were used as the control. Both the DABCYL-Gaba-SQNYPIVQ-EDANS and Suc-LLVY-AMC cleavage signals were measured at an excitation wavelength of 355nm and an emission wavelength of 460nm. On the other hand, an excitation

and emission wavelength of 340 and 425 nm, respectively, was used to monitor the hydrolysis of Bz-RGFFP- 4MβNA. The fluorescence signals were captured at 15-minute intervals with the VICTOR Multilabel plate reader (VICTOR X3). Due to the intrinsic reduction of fluorescence associated with fluorescence resonance energy transfer (FRET)-based cleavage assays, fluorescence from varied concentrations of free Edans (from 0.625 to 40 μM) in the assay buffer was used to generate a standard calibration curve and for correction of the inner filter effect^{33,34}. The obtained relative fluorescence units were converted into velocity {μg (cleaved substrate)/s} and then used to derive the kinetic and catalytic constants in GraphPad Prism v6.0. The enzyme's overall ability to cleave the substrate was represented as k_{cat}/K_M ($M^{-1} s^{-1}$).

Proteolytic assays on polyubiquitin substrates and macromolecules

We incubated 20μg of polyubiquitin substrate (K^{48} -linked) or 0.25mg/mL of bovine serum albumin with 2.0 μM of freshly purified recombinant *PfDdi1* in the 50 mM sodium acetate buffer (as described previously), pH 5.0, in a final volume of 100 μl. Triplicate assays and the control (substrate alone) mixture were incubated at 37°C for 2h. The mixtures were centrifuged and then resolved in a 12% SDS-PAGE. Cleavage of the polyubiquitin substrate was probed using rabbit anti-ubiquitin antibodies and then detected by enhanced chemiluminescence (ECL) using the Bio-Rad ChemiDoc™ MP imaging. On the other hand, cleavage of the BSA substrate was stained by coomassie brilliant blue. The arbitrary band intensity values were presented as means ± standard error (SE).

In vitro culture of *Plasmodium falciparum* and drug treatment

P. falciparum parasites (3D7 strain) were cultured and maintained in purified human red blood cells at 4% hematocrit, in RPMI 1640 medium (Gibco) supplemented with 0.25% Albumax I

(Gibco), 2 g/L Sodium bicarbonate (Sigma), 0.1 mM hypoxanthine (Sigma), and gentamicin (Gibco). Parasite cultures were kept at 37°C with 5% CO₂, 3% O₂, and 92% N₂. The parasites (ring stage; 2-4 hpi) were tightly synchronized with 5% (v/v) D-sorbitol (Sigma) and then monitored by Giemsa staining of methanol-fixed blood smears. Tightly synchronised mid-trophozoites were diluted to 5% parasitaemia and then subjected to the drug treatment (artemisinin; 1µM, DHA; 1µM, MMS; 0.05% or LPV; 50µM, for 4hr. DMSO was used as a vehicle treatment for all the assays. The parasite cell pellets were washed with ice-cold PBS and then lysed with 0.15% (w/v) saponin and radioimmunoprecipitation assay buffer (RIPA buffer) as described previously. The protein content was normalized with BCA assay and then resolved by a 10% SDS PAGE. The gel was transferred to a nitrocellulose membrane blocked with 5% (w/v) skim milk for 1 h at room temperature and probed with primary rabbit anti-ubiquitin antibody (1:100) overnight at 4 °C, followed by HRP-conjugated secondary antibody for 1 h at room temperature. The blots were processed by ECL reagents and then detected using the Bio-Rad ChemiDoc™ MP imaging.

Enzyme inhibition assays

For the enzyme inhibition assays, we preincubated 2.0µM of the enzyme with drug compounds { artemisinin (1µM), DHA (1µM) MMS (0.05%) or LPV (50µM), in sodium acetate buffer, pH 5.0 for 10 minutes, at ~24°C. We then added 10 µM of the fluorescence substrates or 20µg of polyubiquitin protein and the inhibition experiments were carried out at 37°C. The fluorescence signals and the protein degradation were processed as early described. The experiments were carried out in triplicates and fluorescence inhibition was expressed as a percentage of the control.

Protein-drug interaction assays (optical methods; SPR and BLI)

All the SPR or BLI experiments were performed using a T200 instrument (Biacore) or the Bio-Layer Interferometry (BLI) Octet RED96e platform (FortéBio). Freshly prepared HEPES buffered saline (HBS)-EP (0.01 M HEPES; pH 7.4, 0.15 M NaCl, 0.003 M EDTA, 0.05% vol/vol P20 surfactant) or DMSO was used as running buffer for the experiments. For the SPR interaction assay, over 8500 response units (RU) of the recombinant *PfDdi1* in sodium acetate buffer (pH 4.5) was immobilized on a SPR CM5 sensor via amine coupling³⁵. A blank flow cell was used for reference corrections. Heme detoxification protein (HDP) was also immobilized on the CM5 sensor and used as the control protein. For the BLI interaction assay, biotinylated *PfDdi1*, diluted to a concentration of 25 µg/mL in kinetics buffer (HBS-EP with 0.1 mg/ml BSA) was immobilized on streptavidin-coated (SA) biosensors (FortéBio). The ligand was immobilized up to a maximum of 0.8 nm shift. Reference biosensors loaded with the ligand but dipped into wells containing only the buffer were run in parallel to control for possible drifts and establishment of baseline. Serial two-fold dilutions of the compounds; artemisinin (1 µM), lopinavir (50 µM) or MMS (0.05%), diluted in the running buffer, were used and the kinetics performed at 25°C. In the SPR experiments, a total of 0.2 mL of the sample was injected while in BLI, each biosensor was stirred in 0.2 mL of the sample at 1000 rpm. The kinetics data was analyzed using the Biacore T200 evaluation software v3.1 or the Octet Software v10.0. The affinity between the immobilized protein and the compounds was expressed as dissociation constant (K_D).

***PfDdi* 3D model generation and *in silico* docking**

PlasmoDB(<https://plasmodb.org/plasmo/>) and UniProt(<https://www.uniprot.org/>) were used to retrieve sequences for *Ddi1* proteins³⁶. Artemisinin chemical structure was retrieved from PubChem database (<https://pubchem.ncbi.nlm.nih.gov/>). To identify conserved domains in the

PfDdi1 protein, we performed PFAM and INTERPROSCAN search^{37,38}. We then used CLUSTAL-Omega version 1.2.4 to perform multiple sequence alignment³⁹. SWISS-model was used to generate three dimensional (3D) model for *PfDdi1*⁴⁰, and then Rampage tool was used for quality check analysis for the predicted model⁴¹. AutoDock tools were used to perform docking analysis⁴² and the generated images of the molecular models were visualized using PyMol (<https://pymol.org/2/>).

Immunofluorescence assay

Immunofluorescence assay (IFA) was performed with *Plasmodium* parasite cells in suspension. Briefly, parasite pellet was washed in 1×PBS and fixed in 4% v/v formaldehyde supplemented with 0.0075% v/v glutaraldehyde in PBS for 30 min at RT. The cells were then permeabilized in 0.1% Triton X-100 in PBS for 20 min and then washed in 1×PBS. We then blocked with 5% BSA for 1h at room temperature, and then incubated with primary antibodies (anti-Ddi1) overnight at 4°C, followed by incubation with fluorophore-conjugated secondary antibodies (1:100,000 in 3% BSA). DAPI was added and incubated for 20 min. Thin blood smears of the stained cells were made on microscope slides and mounted with cover slips. The slides were imaged using a Nikon Eclipse Ti-E microscope. Images were processed using the NIS-Elements AR (4.40 version) software. For 3D reconstruction, we used Imaris x64 version 6.7 (Bitplane).

In Situ DNA Fragmentation (TUNEL) Assay:

Treated or solvent alone cells (trophozoite-rich) were fixed and permeabilized as described above. DNA fragmentation was assessed by TUNEL using *In Situ* Cell Death Detection Kit, TMR Red (Roche Applied Science, Mannheim, Germany), following the manufacturer's

instructions. Briefly, the permeabilized cells were incubated with TdT enzyme and fluorescein-12-dUTP for 1 h at 37°C, followed by DAPI for 20 min and then washed in 1 × PBS. Thin blood smears of the labeled parasite cells were made on microscope slides and then imaged as described above. The percentage of TUNEL-positive cells was estimated.

Generation of transgenic yeast cells

To know whether the *PfDdi1* is a true yeast orthologue, we performed complementation studies in *S. cerevisiae* yeast cells. We amplified deletion constructs using primers bearing the nourseothricin (NAT) selection marker (Supplementary Table 1). The genes were deleted by homologous recombination and the integration confirmed by PCR-based genotype analysis. On the other hand, the genes encoding full-length *PfDdi1* were amplified from gDNA using primers as shown in supplementary Table 1. The PCR products were cloned into pGPD2 yeast expression vector at SpeI/XhoI site. The constructs were then transformed into the *S. cerevisiae* strain BY4741 by the lithium acetate method⁴³. Selection of transformants were performed by plating over synthetic complete (SC) medium lacking uracil. Deletions were confirmed by genomic DNA PCR with appropriate set of primers (Supplementary Table 1).

Phenotypic characterization

Protein secretion assay and growth rate

The secretion assay was performed following the protocol described by²⁹. Briefly, we inoculated a single colony from each strain into 5mL synthetic complete (SC) medium (0.67% YNB with all amino acids but not uracil) in conical centrifuge tubes. The culture was incubated for 48h at 30°C in an orbital shaking incubator. We then pipetted 1 ml of culture into pre-weighed microcentrifuge tubes and separated the supernatant from pellet by centrifugation for 5 min at 13

000 rpm. The protein content in the supernatant was estimated using the Pierce BCA Protein Assay Kit (Thermo Scientific) with BSA as a standard. The cell pellet was dried at 100°C and weighed. The assays were done in triplicates and the concentration was expressed as milligrams of protein secreted per milligram of dry cell weight.

Treatment with (genotoxic) compounds

Yeast cells were grown to mid log phase and adjusted to 0.1 OD₆₀₀. Serial dilutions were prepared and spotted on SC-based agar plates supplemented with hydroxyurea (50 μM), methylmethanesulfonate (0.05%), camptothecin (6 μg/ml), artemisinin (12 μM), chloroquine (3 mM), or lopinavir (50 μM). The plates were incubated at 30°C for 48 h. For yeast growth curve assays, we followed the protocol as described by⁴⁴, with few modifications, in a liquid handling system (Tecan, Austria). Briefly, we inoculated a 96-well microplate with 5 μL of fresh midlog-phase cell cultures. Each well contained SC media supplemented with either of the compounds in a total volume of 0.2 mL. The cells were incubated for 24 hours at 30°C and the cell population was recorded at an interval of 30 min. All the samples were prepared in triplicates.

Statistical analyses

We exported the data to Excel (Microsoft) and carried out statistical analyses and data representation using SPSS Statistics v16 or GraphPad Prism v6.0. Nonlinear regression analysis was used to determine the enzyme kinetic constants (K_m and V_{max}). The drug binding affinities (K_D values) were calculated after analysis of the association and dissociation from a 1:1 binding model. The results (bars) represent means ± standard error. The authors declare that they have no conflicts of interest with the contents of this article.

Acknowledgement

I thank the International Centre for Genetic Engineering and Biotechnology (ICGEB) for awarding me the Arturo Falaschi ICGEB Predoctoral fellowship (F/KEN18-10) and providing the state-of-the-art facility at the ICGEB, New Delhi component, for the execution of my experiments. This work has been funded by JC Bose fellowship (DST/21/015) conferred to Dr Pawan Malhotra by SIBRI (Department of Science and Technology, India) and Flagship Grant given to ICGEB (DBT/10/026). I am grateful to Dr. Dinakar Salunke for critically reviewing the manuscript. I also thank Prof. Goldberg, Daniel (Washington University) for his enormous contribution and criticism in the development of this manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

References

1. WHO. *World malaria report*. (2019).
2. Ashley, E. A. *et al.* Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. **371**, 411–423 (2014).
3. Phyto, A. P. *et al.* Emergence of artemisinin-resistant malaria on the western border of Thailand: A longitudinal study. *Lancet* **379**, 1960–1966 (2012).
4. Roper, C., Pearce, R., Nair, S., Sharp, B. & Nosten, F. Intercontinental Spread of Pyrimethamine-Resistant Malaria. *Science* (80-.). **305**, 1124 (2016).
5. Das, S., Saha, B., Hati, A. K. & Roy, S. Evidence of Artemisinin-Resistant Plasmodium falciparum Malaria in Eastern India. *N. Engl. J. Med.* **379**, 2018–2020 (2018).
6. Ariey, F. *et al.* A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. *Nature* **505**, 50–55 (2014).
7. Wang, J. *et al.* Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. *Nat. Commun.* **6**, 1–11 (2015).
8. Tilley, L., Strainer, J., Gnädig, N. F., Ralph, S. A. & Fidock, D. A. Artemisinin action and resistance in Plasmodium falciparum. *Trends Parasitol* **32**, 682–696 (2016).
9. Gopalakrishnan, A. M. & Kumar, N. Antimalarial Action of Artesunate Involves DNA Damage Mediated by. *Antimicrob. Agents Chemother.* **59**, 317–325 (2015).
10. Gupta, D. K., Patra, A. T., Zhu, L., Gupta, A. P. & Bozdech, Z. DNA damage regulation and its role in drug-related phenotypes in the malaria parasites. *Sci. Rep.* 1–15 (2016) doi:10.1038/srep23603.
11. Ismail, H. M., Barton, V., Phanchana, M., Charoensutthivarakul, S. & Wong, M. H. L. Artemisinin activity-based probes identify multiple molecular targets within the asexual

- stage of the malaria parasites *Plasmodium falciparum* 3D7. *PNAS* **113**, (2016).
12. Bridgford, J. L. *et al.* Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome. *Nat. Commun.* **3801**, 1–9 (2018).
13. Rocamora, F. *et al.* Oxidative stress and protein damage responses mediate artemisinin resistance in malaria parasites. (2018) doi:10.1371/journal.ppat.1006930.
14. Meuwissen, J. H. *et al.* Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. *Science* (80-.). **347**, 431–436 (2015).
15. Mbengue, A. *et al.* A molecular mechanism of artemisinin resistance in *Plasmodium falciparum* malaria. *Nat. Rev. Microbiol.* **520**, 683–687 (2015).
16. Dogovski, C. *et al.* Targeting the Cell Stress Response of *Plasmodium falciparum* to Overcome Artemisinin Resistance. *PLoS Biol.* **13**, 1–26 (2015).
17. Li, H. *et al.* Structure- and function-based design of *Plasmodium*-selective proteasome inhibitors. *Nature* **530**, 233–236 (2016).
18. Kirkman, L. A. *et al.* Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance. *PNAS* **115**, 6863–6870 (2018).
19. Hunt, P. *et al.* Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria. *Mol. Microbiol.* **65**, 27–40 (2007).
20. Zhang, M. *et al.* Uncovering the essential genes of the human malaria parasite *Plasmodium falciparum* by saturation mutagenesis. *Science* (80-.). **506**, 6388 (2018).
21. Onchieku, N. M. *et al.* Deciphering the targets of retroviral protease inhibitors in *Plasmodium berghei*. *PLoS One* **13**, 1–16 (2018).
22. Lehrbach, N. J. & Ruvkun, G. Proteasome dysfunction triggers activation of SKN-1A / Nrf1 by the aspartic protease DDI-1. *Elife* **5**, 1–19 (2016).

23. Yip, M. C. J., Bodnar, N. O. & Rapoport, T. A. Ddi1 is a ubiquitin-dependent protease. *PNAS* **117**, 7776–7781 (2020).
24. Zhang, H. *et al.* Toxoplasma gondii UBL-UBA shuttle proteins contribute to the degradation of ubiquitinated proteins and are important for synchronous cell division and virulence. *FASEB J.* **34**, 13711–13725 (2020).
25. Bushell, E. *et al.* Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes Article Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. *Cell* **170**, 260-272.e8 (2017).
26. Perteguer, M. J. *et al.* Ddi1-like protein from Leishmania major is an active aspartyl proteinase. *Cell Stress Chaperones* **18**, 171–181 (2013).
27. Hien, T. T. *et al.* Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. *Antimicrob. Agents Chemother.* **48**, 4234–4239 (2004).
28. Serbyn, N., Noireterre, A., Bagdiul, I., Loewith, R. & Δ, Δ. The Aspartic Protease Ddi1 Contributes to DNA- Protein Crosslink Repair in Yeast Article The Aspartic Protease Ddi1 Contributes to DNA-Protein Crosslink Repair in Yeast. *Mol. Cell* **77**, 1066–1079 (2020).
29. White, R. E., Dickinson, J. R., Semple, C. A. M., Powell, D. J. & Berry, C. The retroviral proteinase active site and the N-terminus of Ddi1 are required for repression of protein secretion. *FEBS Lett.* **585**, 139–142 (2011).
30. Miotto, O. *et al.* Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. *Nat. Genet.* **45**, 1–26 (2013).
31. Jelinsky, S. A., Estep, P., Church, G. M. & Samson, L. D. Regulatory Networks Revealed

by Transcriptional Profiling of Damaged *Saccharomyces cerevisiae* Cells : Rpn4 Links.

Mol. Cell. Biol. **20**, 8157–8167 (2000).

32. Li, W. *et al.* Yeast Model Uncovers Dual Roles of Mitochondria in the Action of

Artemisinin. *PLoS Pathog.* **1**, (2005).

33. Zhang, L., Lin, D., Sun, X., Curth, U. & Drosten, C. Crystal structure of SARS-CoV-2

main protease provides a basis for design of improved α -ketoamide inhibitors. *Science*

(80-). **412**, 409–412 (2020).

34. Liu, Y. *et al.* Use of a Fluorescence Plate Reader for Measuring Kinetic Parameters with

Inner Filter Effect Correction. *Anal. Biochem.* **335**, 331–335 (1999).

35. Kamat, V. & Ra, A. Exploring sensitivity & throughput of a parallel flow SPRi biosensor

for characterization of antibody-antigen interaction. *Anal. Biochem.* **525**, 8–22 (2017).

36. Bahl, A. *et al.* PlasmoDB : The Plasmodium genome resource . An integrated database

providing tools for accessing , analyzing and mapping expression and sequence data (both

finished and unfinished). *Nucleic Acids Res.* **30**, 87–90 (2002).

37. Finn, R. D. *et al.* The Pfam protein families database. *Nucleic Acids Res.* **36**, 281–288

(2008).

38. Jones, P. *et al.* Sequence analysis InterProScan 5 : genome-scale protein function

classification. *Bioinformatics* **30**, 1236–1240 (2014).

39. Park, Y. *et al.* The EMBL-EBI search and sequence analysis tools APIs in 2019 F abio.

Nucleic Acids Res. **47**, 636–641 (2019).

40. Kiefer, F., Arnold, K. & Ku, M. The SWISS-MODEL Repository and associated

resources. *Nucleic Acids Res.* **37**, 387–392 (2009).

41. Lovell, S. C. *et al.* Structure Validation by Phi,psi and Cbeta Deviation. *Proteins* **450**,

437–450 (2003).

42. Morris, G. M. *et al.* AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. *J Comput Chem* **30**, 2785–2791 (2010).
43. Ito, H., Fukuda, Y., Murata, K. & Kimura, A. Transformation of Intact Yeast Cells Treated with Alkali Cations. *J. Bacteriol.* **153**, 163–168 (1983).
44. Toussaint, M. & Conconi, A. High-throughput and sensitive assay to measure yeast cell growth : a bench protocol for testing genotoxic agents. *Nat. Protoc.* **4**, (2006).

Figure Legends

Fig. 1: *PfDdi1* hydrolyzes both peptide substrates and proteins. (a) Coomassie stained SDS-PAGE and Western blot analysis using α -His antibodies to detect the purified recombinant *PfDdi1* (~44 kDa) and its processed fragment (~34 kDa). The soluble, recombinant protein was purified using the Ni-NTA resin. (b) Mice or rabbit anti-Ddi1 antibodies detected a band of ~49 kDa from a parasite lysate. (c) Kinetics of substrate hydrolysis. The enzyme was more active on the retropepsin (DABCYL-Gaba-SQNYPIVQ-EDANS) substrate compared to the proteasome (Suc-LLVY-AMC) substrate. (d) Western blot analysis showing the cleavage of polyubiquitin substrate by the *PfDdi1* enzyme. The reaction was incubated for 1 hr at 37°C (e) Coomassie stained SDS-PAGE showing degradation of BSA by the recombinant *PfDdi1*. The samples were resolved in a 12% SDS-PAGE. (f) Quantification of the control and the degraded BSA band intensities (~66 kDa). The units are arbitrary (AU) and the bars show the mean $\pm$ standard error for three independent reactions.

Fig. 2: Artemisinin exposure enhances protein ubiquitination and blocks the *PfDdi1* activity. (a) Western blot analysis showing increased ubiquitination in drug-treated *P. falciparum* parasites compared to the control. (b) Artemisinin (1 μ M) blocked the cleavage of the polyubiquitin substrates. The parasite lysates were probed with rabbit anti-ubiquitin antibodies and the blots are a representative of three independent assays. (c, d) Percentage inhibition of the *PfDdi1* enzyme activity against the retropepsin (c) and proteasome (d) substrate, determined at 3 hours (e) Coomassie stained SDS-PAGE showing inhibition of BSA degradation by *PfDdi1*. (f) Band intensity values of the inhibition of *PfDdi1*-catalyzed BSA degradation by the compounds. The intensity values are represented as arbitrary units (AU). The bars show means $\pm$ standard error for three independent reactions.

Fig. 3: Causal relation between artemisinin-specific DNA fragmentation and *PfDdi1* subcellular localization. (a) Representative IFA images showing artemisinin induces DNA fragmentation in *P. falciparum* parasites. The parasites were subjected to drug pressure for 1hr and then assayed using TdT-mediated dUTP nick end labelling. Fragmentation was observed in more than 95% of the infected RBCs. (b) Increased recruitment of *PfDdi1* into the nucleus following artemisinin pressure compared with control (DMSO). The IFA staining was performed using mice anti-*PfDdi1* antibodies and then underwent

3D reconstruction in IMARIS software. (c) IFA staining of *P. falciparum* blood stage parasites with rabbit anti-*PfDdi1* antibody showing constant expression and localization of Ddi1 in the cytoplasm. The individual stains, merged images, and bright field are shown. Scale bars: 2 μ m. The experiments were performed on 2–4 independent occasions with technical duplicates.

Fig. 4: Artemisinin binds to the recombinant *PfDdi1* protein: SPR, BLI and *In silico* assays. Binding of artemisinin (ART; **a**) and Methylmethanesulfonate (MMS; **b**) showed high affinity interactions with *PfDdi1*, compared to Lopinavir (LPV; **c**), as shown by the K_D values. Two independent SPR or BLI experiments were performed and representative binding sensorgrams are presented. Both the real time binding curves and the global 1:1 fits are shown. The binding kinetics data was analyzed using the Biacore T200 evaluation software v3.1 or the Octet Software v10.0. (c): Artemisinin shows stable interaction with the highly conserved aspartic protease motif “DSG” in *PfDdi1* protein. *PfDdi1* residues present within 4Å of artemisinin and is involved in direct interaction. Homology based 3D model of the *PfDdi1* RVP domain as generated by SWISSMODEL. The conserved Aspartic protease motif DSG is present in the coil region. Red – helix, green – coil, yellow – sheet and blue – conserved active motif.

Fig 5: Ddi1 deficient yeast cells are more susceptible to artemisinin pressure. (a) Ddi1 deficient yeast cells secrete high levels of proteins into the media and *PfDdi1* reverts the protein secretion phenotype to wild type, as did the *ScDdi1* construct. The protein content in the supernatant was estimated using the Pierce BCA Protein Assay Kit and the protein concentration expressed as milligrams of protein secreted per milligram of dry cell weight. Triplicate assays were conducted, and the bars represent means $\pm$ standard error. Spot test images (b) and growth curve assays (c) showing the effect of the compounds on the different yeast lines. Whereas deletion of Ddi1 did not affect the growth fitness of the yeast cells, Ddi1 deficient cells were more susceptible to artemisinin.

Fig. 6: Model demonstrating ART-induced killing of *Plasmodium* parasites. ART has been shown to target several parasite proteins and processes. Here, we focus on the role of the *PfDdi1* in mediating the actions of ART. The ART’s ubiquitous damage of parasite proteins leads to the need for tidying up via the *PfDdi1* or proteasome machinery. Besides causing the protein damage, artemisinin binds to *PfDdi1* and blocks the degradation of the damaged proteins. Besides, ART might be preventing the trafficking of

711 the damaged proteins to the proteasome for degradation. The blockage leads to accumulation of the
712 damaged proteins, choking the parasites thus leading to the ultimate death.

713

714

a

SPR

ART: KD (M): 1.062E-06

BLI

ART: KD (M): 1.556E-06

b

MMS: KD (M): 1.704E-06

MMS: KD (M): 2.507E-04

c

LPV: KD (M): 2.218E-04

LPV: KD (M): 5.619E-04

d